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Prostate cancerUpregulation of Pin1 was shown to advance the functioning of several oncogenic pathways. It was recently
shown that Pin1 is potentially an excellent prognostic marker and can also serve as a novel therapeutic target
for prostate cancer. However, themolecular mechanism of Pin1 overexpression in prostate cancer is still unclear.
In the present study, we showed that the mRNA expression levels of Pin1 were not correlated with Pin1 protein
levels in prostate cell lines which indicated that Pin1 may be regulated at the post-transcriptional level. A key
player in post-transcriptional regulation is represented bymicroRNAs (miRNAs) that negatively regulate expres-
sions of protein-coding genes at the post-transcriptional level. A bioinformatics analysis revealed that miR-296-
5p has a conserved binding site in the Pin1 3′-untranslated region (UTR). A luciferase reporter assay demonstrat-
ed that the seed region of miR-296-5p directly interacts with the 3′-UTR of Pin1 mRNA. Moreover, miR-296-5p
expression was found to be inversely correlated with Pin1 expression in prostate cancer cell lines and prostate
cancer tissues. Furthermore, restoration of miR-296-5p or the knockdown of Pin1 had the same effect on the in-
hibition of the ability of cell proliferation and anchorage-independent growth of prostate cancer cell lines. Our
results support miR-296-5p playing a tumor-suppressive role by targeting Pin1 and implicate potential effects
of miR-296-5p on the prognosis and clinical application to prostate cancer therapy.
© 2014 Published by Elsevier B.V.1. Introduction
Peptidyl-prolyl isomerase, Pin1, is an enzyme that speciﬁcally binds
phosphorylated serine or threonine that immediately precedes proline
(pSer/Thr-Pro) in a subset of proteins [1]. The conformational regulation
catalyzed by Pin1 has amajor effect on key proteins involved in regulat-
ing cell growth, neuronal differentiation, and survival [2]. Moreover,
Pin1 is tightly regulated at multiple levels under physiological condi-
tions. For example, Pin1 expression is subject to E2F or BRCA1-
mediated transcriptional regulation in response to growth factors [3,
4]. In addition to being transcriptionally regulated, Pin1 is also regulated
by post-translational controls, including phosphorylation [5] andine, Medical College, National
704, Taiwan. Tel.: +886 6ubiquitylation [6]. Thus, deregulation of Pin1 has an important role in
a growingnumber of pathological conditions, includingAlzheimer's dis-
ease (AD), aging, asthma and cancer [7–9]. The link between Pin1 and
cancer was originally suggested by the data which showed that Pin1 in-
teracts with a number of phosphoproteins that are cancer-related [10,
11]. Recent studies showed that Pin1 plays an important role in a
wide range of human cancers including lung, breast, colon, and prostate
cancers, and is considered a biomarker of poor prognosis [10–15]. Fur-
thermore, it was reported that Pin1 can affect cancer cell anchorage-
independent growth [16–18]. However, the regulatory mechanism of
Pin1 in prostate cancer tumorigenesis has not been well clariﬁed.
Thus, increasing our understanding of the molecular mechanisms of
Pin1 in prostate cancer tumorigenesis will facilitate our understanding
of prostate cancer progression and could also identify important novel
therapeutic targets for advanced disease.
MicroRNAs (miRNAs) are small non-coding RNAs, which exert re-
pressive effects on translation by targeting the 3′-untranslated region
(UTR) via a 6–8-nucleotide seed region that is critical for coordinating
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expressions of an estimated one-third of human protein-coding genes
involved in fundamental cellular processes, including metabolism, dif-
ferentiation, growth, and apoptosis [21–23]. Aberrant expression of
miRNAs is closely associated with various cancers, including prostate
cancer, breast cancer, gliomas, and lung cancer [24–26]. Therefore, un-
derstanding the molecular mechanisms by which these miRNAs play
roles in deregulating cellular signaling in prostate cancer cells might
help develop better therapeutic strategies for treating this disease. To
date, however, the interaction between miRNAs and Pin1 in prostate
cancer has not been explored.
In this study, we identiﬁedmiR296-5p which speciﬁcally targets the
3′-UTR of Pin1 and consequently regulates Pin1 expression levels. Fur-
thermore, miR-296-5p decreased the ability of cell proliferation and
anchorage-independent growth in prostate cancer cell lines. Restora-
tion of miR-296-5p silenced the expression of the Pin1 protein and de-
pressed prostate cancer cell proliferation. These ﬁndings provide
evidence that miR-296-5p is a suppressor of tumor formation by direct-
ly suppressing oncogenic Pin1 in normal prostate cells and suggest that
miR-296-5p might provide a novel clinical application in prostate can-
cer therapy.
2. Materials and methods
2.1. Cell cultures
PC-3, LNCaP, and 22Rv1 cell lines (ATCC, Manassas, VA, USA) were
cultured in RPMI-1640, supplemented with 10% fetal bovine serum
(FBS) and antibiotics. The DU145 (ATCC) cell line was cultured in min-
imum essential Eagle's medium supplemented with 10% FBS and
2 mM L-glutamine with antibiotics. The PZ-HPV-7, PWR-1E and
RWPE-1 (ATCC) human nontumorigenic prostate epithelial cell lines
were cultured in keratinocyte serum-free medium supplemented with
5 ng/ml human recombinant epidermal growth factor and 30 mg/ml
bovine pituitary extract (Invitrogen, Carlsbad, CA). Cultures were main-
tained in a 5% CO2 humidiﬁed atmosphere at 37 °C.
2.2. Clinical specimens
Human prostate specimenswere obtained fromKaohsiung Veterans
General Hospital (Kaohsiung, Taiwan), National Cheng Kung University
Hospital (Tainan, Taiwan) and Wan Fang Hospital, Taipei Medical Uni-
versity (Taipei, Taiwan). All patients gave informed consent, and the
protocol was approved by the IRB Committee before a tissue sample
was collected during their planned surgery. Carcinoma samples were
obtained from palliative transurethral excisions of the prostate, and he-
matoxylin and eosin-stained tumor tissue sections were examined by a
pathologist. The benign prostate hyperplasia (BPH) samples were ob-
tained from a transurethral resection of the prostate (TURP) from pa-
tients and prostatic intraepithelial neoplasia (PIN) was removed from
each surgical specimen. Specimens were histologically veriﬁed to con-
tain no prostate cancer cells.
2.3. Western blot analysis
Cell lines and human prostate cancer specimens were placed in lysis
buffer at 4 °C for 1 h. The protein samples were electrophoresed using
12% SDS-polyacrylamide gel electrophoresis (PAGE) and performed as
previously described [27].
2.4. Reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from clinical tissues and cell lines using the
TRIzol reagent (Invitrogen), and complementary DNA (cDNA) was syn-
thesized from 1 μg of total RNA using an M-MLV reverse-transcriptase
system kit (Invitrogen) according to the manufacturer's protocol. Afterthe PCR ampliﬁcation, the results were analyzed by 1% agarose gel elec-
trophoresis. The primer sequences were: Pin1-F, ATGGCGGACGAGGA
GAAGCTGC and Pin1-R, TCACTCAGTGCGGAGG-ATGATG; and GAPDH-
F, TGGTATCGTGGAAGGACTCA and GAPDH-R, AG-TGGGTGTCGCTGTT
GAAG.
2.5. In situ hybridization (ISH) and immunohistochemistry (IHC)
The ISH assay was performed as described previously [28]. In brief,
the human prostate specimens were ﬁxed for 24 h in 4% paraformalde-
hyde. The expression of miR-296-5p was detected by using a
digoxigenin (Dig)-conjugated miR-296-5p probe (Exiqon, Denmark)
on parafﬁn embedded prostate tissue. The signals were ampliﬁed with
an NBT/BCIP chromogen at 37 °C using the in situ hybridization kit
(Biochain). Finally, sections were counterstained with Nuclear Fast
Red. For IHC, the sections were treated with 3% H2O2/methanol and in-
cubatedwith anti-Pin1 antibody (1:1000) for 4 °C overnight afterwash-
ing with phosphate-buffered saline (PBS). The sections were then
allowed to react with the horseradish peroxidase polymer-conjugated
secondary antibodies, incubatedwith aminoethyl carbazole (AEC) chro-
mogen, and then counterstained with hematoxylin.
2.6. Human protein atlas
In silico approach to analyze Pin1 protein levels in prostate tissues
was performed by analyzing the web site of Human Protein Atlas
(http://www.proteinatlas.org/). As indicated in the web site, the inten-
sity (fraction of positive cells)was combined into a four-grade scale rep-
resented by the colors, white for negative, yellow for weak, orange for
moderate, and red for strong level of protein expression, and the quan-
tity for white color is less than 25%, the quantity for yellow or orange
colors is between 25% and 75%, and the quantity for red color is over
75%.
2.7. Reagents, antibodies, and expression constructs
MiRNA and anti-miR oligonucleotides were purchased from Applied
Biosystem (Invitrogen). The Pin1 short hairpin RNA (shRNA) expression
vector in themammalian expression vector, pGIPZ, was provided by Dr.
Michael Hsiao. The anti-Pin1, cyclin D1 and β-actin antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.8. Construction of the 3′-UTR-luciferase plasmid and reporter assays
The Pin1 3′-UTR target site was ampliﬁed by PCR using the primers
Pin1-WT-UTR-Rev (5′-AAGCTTAGTGGTTCTGGGTTTAATTGGGGGTGAA
AG-3′) and Pin1-WT-UTR-Fwd (5′-ACTAGTGGGTGGGGAGCCCAGG
CCT-3′) cloned downstream of the luciferase gene in the pMIR-
REPORT luciferase vector (Invitrogen). This vector was sequenced and
named Pin1-WT-UTR. Site-directed mutagenesis of the miR-296-5p
target-site in the Pin1 3′-UTRwas carried out using a Quick-changemu-
tagenesis kit (Stratagene, Heidelberg, Germany) and named Pin1-Mut1-
UTR and Pin1-Mut2-UTR, in which Pin1-WT-UTR was used as a tem-
plate. For the reporter assays, cells were transiently transfected with a
wild-type (WT) or mutant reporter plasmid, miRNA oligonucleotides
using Lipofectamine 2000 (Invitrogen). The reporter assay was per-
formed at 48 h post-transfection using the Dual-Luciferase Reporter
Assay system (Promega, Madison, WI, USA).
2.9. Quantitative RT-PCR assays for mature miRNA
The RT reactions of cell lines or human prostate cancer specimens
were performed in a reaction containing 10 ng total RNA. Speciﬁc prod-
ucts were ampliﬁed and detected using the Roche LightCycler detection
systemwith the cycle proﬁle according to the TaqMan qRT-PCR miRNA
Detection Kit (Invitrogen). The relative gene expression was calculated
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target PCRCt valueswere normalized by subtracting the internal control
of the RNU6B snoRNA Ct value.
2.10. Cell-cycle analysis
22Rv1 cells were transfected with pre-miR-NC or pre-miR-296-5p
molecules for 48 h and cell-cycle analysis was then performed. The dis-
tribution of cell-cycle phases was assayed by propidium iodide staining
and ﬂow cytometry (FACScan; BD Biosciences, San Jose, CA, USA).
2.11. Cell viability assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays as reported previously
[29]. Cells were transiently transfected with pre-miR-NC or pre-miR-
296-5p oligonucleotide using Lipofectamine 2000 prior to plate onto
96-well plates (104 cells/well).
2.12. Soft-agar colony formation assay
The effect of pre-miR-296-5p on anchorage-independent growth
was assessed with a soft-agar colony formation assay. For the soft-
agar assay, cells seeded on 35-mm dishes at 60%–80% conﬂuence were
transfected using Lipofectamine 2000 with a concentration of 30 nM
of the pre-miR-NC or pre-miR-296-5p oligonucleotide. Agarose (0.5%)
containing RPMI/10% FBS medium was added to 6-well plates as the
lower layer. Twenty-four hours later, cells were trypsinized, split into
0.35% agarose containing RPMI/10% FBS medium and plated at 5000
cells/well in 6-well dishes. After 10 to 14 days, colonies were stained
with 0.1% crystal violet solution and counted.
2.13. Pin1-shRNA preparation and transient transfection
22Rv1 cell line was cultured in 100-mm-diameter antibiotic-free
medium. The next day, cells were infected with Pin1-shRNA-carrying
virus medium in culture plates (to 60%–80% conﬂuency) for 24 h
twice, replaced with fresh culture medium and cultured in a 37 °C, 5%
CO2 incubator. To select stably transfected cells, cells were transferred
to medium containing 4 μg/ml puromycin for selection for 3 weeks,
and the stable suppression of Pin1 was checked by Western blot
analysis.
2.14. Statistical analysis
Statistical analyses were performed as recommended by an inde-
pendent statistician. These included unpaired Student's t-test (miR-
quantitative RT-PCR, luciferase reporter assay, soft-agar assay, cell pro-
liferation, and Western blot quantiﬁcation) and paired Student's t-test
(Western blot quantiﬁcation of NT pair tissues). Relationships between
expression levels of Pin1 and prostate cancerwere analyzed by aχ2 test.
The correlation of levels of miR-296-5p and Pin1 was determined using
Spearman's test. All statistical analyses were performed using SPSS
software (SPSS, Chicago, IL, USA), all values are expressed as the
mean ± standard error (SE), and statistical signiﬁcance was accept-
ed for p b 0.05.
3. Results
3.1. Pin1 is upregulated in prostate cancer specimens
To determine whether Pin1 expression levels were upregulated in
clinical prostate cancer, we ﬁrst analyzed Pin1 expression in parafﬁn-
embedded clinical prostate cancer specimens by IHC. Strikingly, Pin1
levels were signiﬁcantly upregulated in tumor tissues compared with
normal tissues (Fig. 1A and D). Furthermore, as shown in Fig. 1D,positive staining signals of Pin1 were mainly distributed in the cyto-
plasm and nuclei of cells. In addition, moderate Pin1-positive staining
was observed in tissues with hyperplasia (HP) (Fig. 1B) and prostatic
intraepithelial neoplasia (PIN) (Fig. 1C). To complement the Pin1 pro-
tein expression data of prostate cancer tissues, we utilized an in silico
approach to analyze Pin1 protein levels in prostate tissues (Fig. 1E).
Results showed a similar trend when looking at IHC staining patterns
in normal and prostate cancer tissues via the Human Protein Atlas data-
base [30,31], an antibody-based protein atlas containinghistological im-
ages. Results of this data showed that there were 22 (95.6%) prostate
cancer tissues with N75% positive staining with Pin1 (Fig. 1E) which
indicates high expression of the Pin1 protein in prostate cancer tissues
compared to benign prostate glands (p b 0.001, by the χ2 test). Col-
lectively, these results suggest that overexpression of Pin1 may be
associated with prostate tumorigenesis.
3.2. Identiﬁcation of miRNA candidates targeting the Pin1 3′-UTR of
prostate cancer cells
To understand the molecular mechanism causing the upregulation
of Pin1 and its possible role in oncogenesis of prostate cancer, we ﬁrst
analyzed the expression levels of Pin1 protein and mRNA in several
cancer cell types (prostate cancer, lung cancer, esophagus cancer,
and breast cancer) byWestern blot and RT-PCR analyses, respective-
ly. Compared to three nontumorigenic prostate epithelial cell lines
(PZ-PHV-7, RWPE-1, and PWR-1E), the Pin1 protein was highly
expressed in prostate cancer cell lines, including DU145, 22Rv1,
PC-3, and LNCaP (Fig. 2A, upper panel). Interestingly, mRNA and
protein levels of Pin1 did not show any similar trend between
nontumorigenic prostate epithelial cell lines and prostate cancer
cell lines (Fig. 2A, lower panel). However, this correlation between
mRNA and Pin1 protein levels was not observed in cell lines of
other cancer types, including lung, esophagus, and breast cancers
(Supplementary Fig. 1A–C). Inconsistent changes between the
mRNA and protein strongly imply that the upregulation of the Pin1
protein in prostate cancer cell lines may be regulated at the post-
transcriptional level. A key player in post-transcriptional regulation
is represented by miRNA that controls approximately 60% of all
protein-coding genes to be predicted to contain miRNA-binding
sites within their 3′-UTR [32]. To identify candidate miRNAs
targeting the Pin1 3′-UTR, the PicTar [33], TargetScan [34], miRnada
[35], microRNA.org [36] and microcosm [37] databases were used
which identiﬁed ten candidate miRNAs with the potential to interact
with the Pin1 3′-UTRwhichwere predicted by at least two of the ﬁve
bioinformatics databases (Supplementary Table 1). Among these ten
candidates, the miR-200 family of miRNAs (miR-200b/200c/429)
and miR-296-5p was predicted by at least three databases and
found to be frequently dysregulated in prostate cancer [38–40]. To
determine whether these candidate miRNAs were involved in regu-
lating Pin1 expression and serve as putative tumor suppressors in
prostate cancer, we ﬁrst analyzed the structural symmetry of the pre-
dicted miRNA–mRNA binding complexes. An RNAhybrid software [41]
analysis revealed that miR-296-5p contained two target sites of the 3′-
UTR of Pin1 (Fig. 2B) with minimal free energy, ΔG =−32.5 kcal/mol
for site 1 and ΔG =−30.4 kcal/mol for site 2, whereas miR-200c and
miR-429 contained only one target site of the 3′-UTR of Pin1, respective-
ly (Supplementary Fig. 2A and B, upper panel). To determine whether
these candidate miRNAs serve as a putative tumor suppressor in pros-
tate cancer, expression levels of miR-200c, miR-429, and miR-296-5p
in three nontumorigenic prostate epithelial cell lines and four prostate
cancer lines were detected by the miRNA-quantitative RT-PCR analysis.
Among these three miRNAs, miR-296-5p was the only miRNA that
exhibited high expressions in nontumorigenic prostate epithelial cell
lines and was diminished in four prostate cancer cell lines (Fig. 2C,
Supplementary Fig. 2A and B, lower panel). Across all seven cell lines
tested, we found an inverse correlation between Pin1 protein levels
Fig. 1. Expression of Pin1 in human prostate cancer tissues. (A) Normal prostate tissue negatively stained for Pin1 expression. (B and C) Moderate staining of Pin1 in HP and PIN tissues.
(D) Prostate tumor tissuewith overexpression of Pin1 protein showing strong staining of themajority of cells (brown) in the tumor areas. (E) Pin1 protein expression levels obtained from
the Human Protein Atlas database. The percentage of cases is indicated on the y-axis, whereas the type of sample is shown on the x-axis.
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cient [r] =−0.703); however, there was no association between Pin1-
mRNA and miR-296-5p (Fig. 2A, lower panel, 2C, Spearman correlation
coefﬁcient [r] = 0.847). These experiments suggested that miR-296-
5p might negatively regulate Pin1 at the post-transcriptional level.
3.3. MiR-296-5pwas downregulated in prostate cancer tissues and showed
an inverse correlation with Pin1 expression
To evaluate the correlation between Pin1 and miR-296-5p in pros-
tate cancer tissues, we ﬁrst analyzed the miR-296-5p expression levels
from a publicly available dataset, deposited in theNCBI Gene Expression
Omnibus (GEO)under accession no. GSE21032 [42]. As shown in Fig. 3A,
we observed that the miR-296-5p expression was signiﬁcantly down-
regulated in the clinical T2 stage of prostate cancer tissues compared
to the normal group (Fig. 3A, middle panel) (p = 0.03). However,
therewasno statistically signiﬁcant (NS) difference between the clinical
T1c stage group and normal group (Fig. 3A, left panel) or the clinical T3stage group and normal group (Fig. 3A, right panel). Individual expres-
sion values of miR-296-5p in different clinical stages of prostate cancer
tissues are shown in Supplementary Fig. 3. These results reveal that
prostate cancer tissues had low miR-296-5p expression, especially in
the clinical T2 stage group. Moreover, the mRNA level of Pin1 was also
analyzed in the same GEO dataset. As shown in Fig. 3B, we observed
that Pin1 mRNA levels did not have the signiﬁcant difference between
normal group and different clinical stage groups. Next, we performed
ISH and IHC staining on consecutive tissue sections to investigate
whether there was an inverse correlation between the miR-296-5p
and Pin1 protein in prostate cancer tissues. Fig. 3C shows the represen-
tative images of the miR-296-5p and Pin1 protein expressions in pros-
tate cancer tissues and reveals low levels of the miR-296-5p in clinical
specimens (Fig. 3C, upper panels I, II and III) and relatively high Pin1
protein expression (Fig. 3C, bottom panels IV, V and VI). Staining scores
were obtained and deﬁned from the immunoexpression of IHC and ISH
(Supplementary Fig. 4) and indicated a highly inverse correlation be-
tween miR-296-5p and Pin1 expressions in prostate tumor tissues
Fig. 2. The Pin1 3′-UTR is the target of miR-296-5p and is inversely correlated with miR-296-5p expression in prostate cancer cells. (A) Pin1 protein expression levels in three
nontumorigenic prostate epithelial cell lines (PZ-PHV-7, RWPE-1, and PWR-1E) and four prostate cancer cell lines (DU145, 22Rv1, PC-3, and LNCaP). (B) Depiction illustrating that two
complementary sites of miR-296-5p are complementary to the 3′-UTR of Pin1 and are conserved in three different species. (C) MiR-296-5p expression in a panel of prostate cell lines.
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n = 27). To further conﬁrm the lower miR-296-5p level in prostate
cancer cells with higher Pin1 expression, the ﬁve NT paired tissues
were used for miR-296-5p and Pin1 expression examination. The
tumors had lower levels of miR-296-5p than their adjacent nontumor
tissues (Fig. 3E, bottom panel, p b 0.01) and had higher levels of Pin1
protein than the nontumor tissues (Fig. 3E, upper panel, p b 0.05). Col-
lectively, these results indicated that high miR-296-5p levels in normal
prostate cells played a tumor-suppressor role by negatively regulating
Pin1 expression and downregulation of miR-296-5p may be involved
in prostate cancer tumorigenesis.
3.4. MiRNA-296-5p directly targets the 3′-UTR of Pin1
To further verify the targeting of Pin1 bymiR-296-5p, theWT3′-UTR
of Pin1 was cloned downstream of the luciferase open reading frame
(referred to as Pin1-WT-UTR) (Fig. 4A). In a parallel experiment, theconserved miR-296-5p targeting sequence, GGGGGCCC, of sites 1 and
2 within the 3′-UTR of Pin1 was individually mutated to GGUCCAGA
(referred to as Pin1-Mut1-UTR and Pin1-Mut2-UTR, respectively)
(Fig. 4A). Negative control miRNA (pre-miR-NC) or the precursor of
miR-296-5p (pre-miR-296-5p) was cotransfected with the Pin1-WT-
UTR luciferase construct. As shown in Fig. 4B, transfection with the
pre-miR-296-5p led to a signiﬁcant decrease in luciferase activity com-
pared to the pre-miR-NC (Fig. 4B, a 50% decrease compared to lanes 2
and 3, p b 0.05). In contrast, co-transfection of anti-miRNA of miR-
296-5p (anti-miR-296-5p) with the Pin1-WT-UTR plasmid in HEK-
293T cells signiﬁcantly increased luciferase activity compared to co-
transfection of the negative control anti-miRNA (anti-miR-NC)
(Fig. 4B, lanes 4 and 5, p b 0.01). The same result of luciferase assay on
22Rv1 cell line was also observed (Fig. 4D). Next, to identify which
miR-296-5p-binding site of the Pin1 3′-UTR is critical for miR-296-5p
binding, the Pin1-Mut1-UTR and Pin1-Mut2-UTRwere used in the lucif-
erase reporter assay. As shown in Fig. 4C and E, the luciferase activity of
Fig. 3. Expression level of Pin1 was inversely correlatedwithmiR-296-5p in prostate cancer tissues. (A) Relative expression levels of miR-296-5p andmRNA levels of Pin1 (B) in different
clinical stages of prostate cancer tissues analyzed using the public GEO database. (C) Photomicrographs illustrating serial sections to compare Pin1 (immunoreactivity) and miR-296-5p
(in situ hybridization) expressions in parafﬁn sections of human prostate cancer tissues. The nucleus is stainedwith hematoxylin (blue) or Nuclear Fast Red (red). The cytoplasm is stained
with eosin (purple). Pin1 was detected using a Pin1 monoclonal antibody (brown). MiR-296-5p was detected using a miR-296-5p probe (blue). Black bars are the actual size of magni-
ﬁcation. (D) Expression levels indicating an inverse correlation between Pin1 and miR-296-5p expressions in prostate tumor tissues (r = −0.638, p b 0.001, n = 27). NS: No
statistically signiﬁcant. (E) The level of Pin1 protein expression was inversely correlated with miR-296-5p expression in the representation of ﬁve NT pair prostate cancer spec-
imens. *p b 0.05, **p b 0.01, ***p b 0.001.
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Fig. 4. Pin1 is the direct target ofmiR-296-5p. (A)Diagramof the Pin1 3′-UTR-containing constructs. The Pin1 3′-UTR is labeled Pin1-WT-UTR. Binding sites 1 and 2 are respectively labeled
Pin1-Mut1-UTR and Pin1-Mut2-UTR. The wild-type (WT) reporter vector was respectively cotransfected with pre-miR-NC, pre-miR-296-5p, anti-miR-NC, and anti-miR-296-5p in HEK-
293T cell line (B) or 22Rv1 cell line (D). TheMut1 andMut2 reporter vectorswere respectively cotransfectedwith pre-miR-NC and pre-miR-296-5p inHEK-293T cell line (C) or 22Rv1 cell
line (E). NS: Not statistically signiﬁcant.
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UTR reporter construct was abolished by miR-296-5p that mediated
the Pin1 3′-UTR luciferase activity that was suppressed by the simulta-
neous transfection of pre-miR-296-5p (Fig. 4C and E, lanes 2 and 3).
However, the inhibitory effect of pre-miR-296-5p on luciferase activityremained in Pin1-Mut2-UTR-transfectedHEK-293T and 22Rv1 cell lines
(Fig. 4C and E, lanes 5 and 6). These results indicated that site 1 of the
Pin1 3′-UTR was the major target for miR-296-5p to suppress Pin1 pro-
tein expression. Taken together, these data suggest that miR-296-5p
binds to the 3′-UTR of Pin1 and regulates Pin1 protein expression.
Fig. 5.MiR-296-5p inhibits growth of 22Rv1prostate cancer cells in vitro. (A) Validation of themiR-296-5p expression level after transfectionwith themiR-296-5pprecursor for 48 and 72
h in the 22Rv1 cell line. (B) Pin1 protein level after overexpression ofmiR-296-5p in the 22Rv1 cell line. After transfection, the total protein was extracted and used forWestern blot anal-
ysis. Quantiﬁcation of Pin1 expression by the ratio of Pin1/β-actin. (C) The proliferative ability of 22Rv1 cells aftermiR-296-5p transfectionwas signiﬁcantly reduced compared to the con-
trol anti-miR orMock. (D) Soft agar colony formation assayswere performed 24 h after transfection (upper panel). Quantiﬁcation of the soft-agar assay in transient transfected 22Rv1 cells
(lower panel). (E) After 48 h of transfection, endogenous Pin1 was suppressed by ectopic miR-296-5p transfection byWestern blot analysis. (F) After transfection, cell growth was mea-
sured in the indicated time points byMTT assay. Anti-growth effect of ectopicmiR-296-5pwas attenuated by co-transfection of Pin1-expressing plasmid. (G) Suppressed cell proliferation
rate by miR-296-5p was rescued by ectopic Pin1 expression by soft agar colony formation assays. *p b 0.05, **p b 0.01.
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2063K.-H. Lee et al. / Biochimica et Biophysica Acta 1843 (2014) 2055–20663.5. Growth inhibitory effect of miR-296-5p on prostate cancer cells by
directly inhibiting Pin1
We then investigated the inhibitory effects of overexpression of
miR-296-5p on the development of prostate cancer. First, to determine
whether the overexpression of miR-296-5p in cancer cells with a low
miR-296-5p level can decrease the Pin1 protein level, the 22Rv1 pros-
tate cancer line was transiently transfected with pre-miR-296-5p or
pre-miR-NC. MiR-quantitative RT-PCR and Western blot experiments
were performed to detect the mature miR-296-5p level and Pin1 pro-
tein level. Compared to pre-miR-NC transfection, the results showed
that pre-miR-296-5p transfection resulted in about a 104-fold increase
of mature miR-296-5p in the 22Rv1 cell line examined at a time course
of 48 and 72h (Fig. 5A). As expected, therewas a signiﬁcant reduction in
the Pin1 protein amount in pre-miR-296-5p-transfected 22Rv1 cells
(Fig. 5B). Quantiﬁcation of Pin1 protein expression showed that it was
reduced by about 50% at 48 h and by 60% at 72 h after transfection
(Fig. 5B). Similar results were also observed in another prostate cancer
cell line, PC-3 (Supplementary Fig. 5A and B). These data suggest that
miR-296-5p speciﬁcally downregulates Pin1 at the post-transcriptional
level. It was demonstrated that Pin1 plays a pivotal role in cellular pro-
liferation of prostate cancer [43]. We next examined the effect of miR-
296-5p on the cell proliferation ability with the MTT proliferation
assay. 22Rv1 and PC-3 cells were plated onto a 96-well culture plate
(104 cells/well), and the proliferation rate was measured at the indicat-
ed times (24, 48, 72, and 96 h). Transient transfection of pre-miR-296-
5p resulted in a signiﬁcant decrease in miR-296-5p-transfected 22Rv1
or PC-3 cells growth compared to the groups of mock and pre-miR-
NC-transfected 22Rv1 or PC-3 cell lines, respectively (Fig. 5C, Supple-
mentary Fig. 5C). To investigate the effect of miR-296-5p-mediated sup-
pression of Pin1 on the tumorigenic phenotypes of prostate cancer cells,
we examined the effect ofmiR-296-5p-mediated suppression of Pin1 on
anchorage-independent colony formation. Strikingly, we found that
enforced expression of miR-296-5p in 22Rv1 (Fig. 5D) or PC-3 (Supple-
mentary Fig. 5D) prostate cancer cell lines drastically inhibited their
anchorage-independent growth ability, as shown by decreased colony
numbers and sizes. To make a sufﬁcient functional link between miR-
296-5p and Pin1, we performed the rescue experiment by introducing
Pin1-expressing plasmid (pEGFP-Pin1) or empty vector in the presence
or absence of ectopic pre-miR-296-5p expression in prostate cancer
cells. Ectopic pre-miR-296-5p expression attenuated endogenous Pin1
protein expression, thereby led to the suppression of cellular growth
and proliferation in both MTT and anchorage-independent colony for-
mation assay (Fig. 5E–G for 22Rv1 cells, Supplementary Fig. 5E–G for
PC-3 cells). Importantly, this anti-growth effect of ectopic pre-miR-
296-5p was attenuated by co-transfection of Pin1-expressing plasmid.
Note that miR-296-5p suppresses endogenous Pin1 protein expression
in both 22Rv1 and PC-3 cell lines (Fig. 5E, lanes 2 and 4, Supplementary
Fig. 5E, lanes 2 and 4). Moreover, anti-growth effect of miR-296-5p was
signiﬁcantly attenuated by ectopic GFP-Pin1 expression (Fig. 5F and G of
22Rv1 cells, Supplementary Fig. 5F and G of PC-3 cells). This result clar-
iﬁes that miR-296-5p directly targets and suppresses Pin1, and that
overexpression of Pin1 can abolish pre-miR-296-5p-mediated growth
suppression. In addition, when we assessed the effect of miR-296-5p
on cell cycle distribution,we observed thatmiR-296-5p induced a signif-
icant change in G2/M arrest to compare to pre-miR-NC (Supplementary
Table 2 and Supplementary Fig. 6A, p b 0.05). The levels of cyclin D1 in
the G2/M phase of cell cycle are crucial for the cells to decide if they
have to undergo another round of replication [44]. Moreover, Pin1 has
been demonstrated to positively regulate cyclin D1 by transcriptional
activation and posttranslational stabilization [3]. We then examined
the expression of cyclin D1 in miR-296-5p-expressing cells by Western
blot analysis. As we expected, ectopic expression of pre-miR-296-5p
suppressed expression of Pin1 and cyclin D1 proteins (Supplementary
Fig. 6B). Taken together, this result indicated that miR-296-5p induced
anti-growth effect through Pin1-mediated regulation of cyclin D1expression in prostate cancer cells. To conﬁrm the function of miR-
296-5p in nontumorigenic prostate epithelial cells, anti-miR-296-
5p was used to investigate whether downregulation of endogenous
miR-296-5p expression in nontumorigenic prostate epithelial cells
could increase the Pin1 protein level and promote cell growth. The
anti-miR-296-5p oligonucleotides was transiently transfected into
PZ-HPV-7 cell line. The expression of miR-296-5p was signiﬁcantly
downregulated in anti-miR-296-5p-transfected PZ-HPV-7 cells (Sup-
plementary Fig. 7A, with about 70% and 90% reductions at 48 and 72
h, respectively) compared to anti-miR-NC. Expression levels of the
Pin1 protein increased by about 50% at 48 h after transfection (Supple-
mentary Fig. 7B), and statistical analysis of Pin1 protein quantiﬁcation
showed that there was a signiﬁcant difference between anti-miR-NC-
transfected and anti-miR-296-5p-transfected cells in three indepen-
dent experiments (Supplementary Fig. 7C, p b 0.05). In addition, cell vi-
ability results showed that there was a 30% increase in anti-miR-296-
5p-transfected PZ-HPV-7 cells compared to the mock and anti-miR-
NC-transfected groups at 72 and 96 h after transfection (Supplementary
Fig. 7D, p b 0.01). These results suggest that upregulation of miR-296-
5p can downregulate the Pin1 protein level and inhibit prostate cancer
cell proliferation and prostate cancer cell tumorigenicity in vitro.
3.6. Effect of Pin1 knockdown on prostate cancer cells
A previous study [43] and our data showed that overexpression of
Pin1 contributes to the promotion of cell proliferation. In order to verify
the Pin1-regulated cell proliferation of prostate cancer cells, the 22Rv1
prostate cancer cell line was infected with lentiviral particles carrying
shRNA of Pin1. As shown in Fig. 6A, Pin1 protein expression levels
were signiﬁcantly reduced in cells expressing Pin1 shRNA-7-22Rv1
and shRNA-12-22Rv1 (about 78% and 41% reductions, respectively). In
our study, we showed that the Pin1 protein level was modulated by
miR-296-5p in prostate cancer cells (Fig. 5B). To investigate whether
the phenotype of Pin1-speciﬁc knockdown is similar to miR-296-5p's
function, we performed the MTT proliferation and soft agar colony
formation assays of the 22Rv1 cell line. The proliferation index of
Pin1 stably knocked-down 22Rv1 cells signiﬁcantly decreased in
both shRNA-7 and shRNA-12 groups compared to the parental
group (Fig. 6B, p b 0.01). Moreover, anchorage-independent growth
of 22Rv1 cells in both shRNA-7 and shRNA-12 stably knocked-down
Pin1 was also signiﬁcantly reduced (Fig. 6C, p b 0.001). The same
results were also observed in PC-3 cells that were transiently
transfected with Pin1 shRNA (Supplementary Fig. 8). These data in-
dicate that the effect of Pin1-speciﬁc knockdown concurs with the
effect of miR-296-5p, and Pin1 is a critical regulator of prostate can-
cer oncogenesis.
4. Discussion
It was reported that Pin1 is strikingly overexpressed in a subset of
human tumors, and high Pin1 expression is correlated with cancer de-
velopment and a poor prognosis in patients with prostate cancer [12,
45]. However, themechanism of Pin1 overexpression in prostate cancer
is still unclear. The present study established for the ﬁrst time the im-
portant role played by miR-296-5p in inhibiting expression of the Pin1
oncoprotein in prostate cancer. There are several lines of evidence that
support this conclusion which are listed below. First, Pin1 was signiﬁ-
cantly upregulated in prostate tumor tissues compared to normal tis-
sues from our IHC results and the Human Protein Atlas database.
Second, signiﬁcantly decreased expression of miR-296-5p in prostate
cancer tissues at clinical T2 stage compared to the normal groupwas de-
termined from the Taylor dataset [42]. Third, expressions ofmiR-296-5p
and Pin1 were found to be signiﬁcantly inversely correlated in resected
prostate cancer tissues. Fourth, overexpression of miR-296-5p in 22Rv1
prostate cancer cells decreased Pin1 expression, and the cell prolifera-
tive ability and tumorigenic activity. Fifth, targeting miR-296-5p by
Fig. 6. Stable knockdown of Pin1 suppresses cell proliferation and anchorage-independent growth of prostate cancer cells. (A) Expression of Pin1 was detected in Pin1 stably knocked-
down 22Rv1 cells byWestern blot. Quantiﬁcation of Pin1 expression by the ratio of Pin1/β-actin. (B)MTT assay of Pin1 stably knocked-down 22Rv1 cells. (C) Soft-agar assay of Pin1 stably
knocked-down 22Rv1 cells (upper panel). Quantiﬁcation of soft-agar assay in Pin1 stably knocked-down 22Rv1 cells (lower panel). *p b 0.05, **p b 0.01, ***p b 0.001.
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al cells dramatically augmented the cell growth ability. Collectively, this
study is the ﬁrst to report that Pin1 is negatively regulated bymiR-296-
5p and also showed that miR-296-5p is a signiﬁcant suppressor of
prostate cancer tumorigenesis, as evidenced by studies using cell lines,
clinical samples, and GEO prostate cancer dataset analyses.
Typically, miRNAs exert their function by affecting multiple genes.
Thus, one miRNA may have different functions when interacting with
different targets [46]. Among these miRNAs, miR-296-5p was recently
found to be progressively lost during tumor progression and was corre-
lated with metastatic disease in colorectal, breast, lung, parathyroid,
liver, and bile duct cancers [47–49]. Furthermore, miR-296-5p was
found to be located on chromosome 20q13.32, and it was reported
that the 20q13.32–13.33 chromosome region is deleted in 20% of pros-
tate cancer patients [50]. In a recent study, it was demonstrated that
miR-296-5p modulates tumor invasiveness by modulating HMGA1 ex-
pression in prostate cancer cells [40]. Overexpression of HMGA1 in
prostate cancer cell lineswas found to be associatedwith highly aggres-
sive growth and a relatively high degree of metastatic potential [51].
MiR-296-5p has an especially negative impact on HMGA1 translation
and also enhances HMGA1 degradation. As a result, tumor progressionis markedly attenuated [40]. Importantly, these observations concur
with our analysis of the Taylor dataset which showed signiﬁcantly de-
creased expression of miR-296-5p in clinical T2 stage but not in T1
stage prostate cancer tissues compared to the normal group. Moreover,
there is no statistical signiﬁcance of miR-296-5p expression in clinical
T3 stage of prostate cancer tissues compared to the normal group due
to small sample sizes. In addition, overexpression of miR-296-5p in
prostate cancer cells was found to signiﬁcantly suppress cell prolifera-
tion and anchorage-independent growth through inhibition of Pin1
protein expression. Collectively, these results showed that miR-296-5p
acts as a suppressor of malignant transformation and progression by at-
tenuating its target transcription in different types of cancer.
The prostate-speciﬁc antigen (PSA) is commonly used for popula-
tion screening, diagnosis, and monitoring of patients with prostate
cancer [52]. Recent research suggests that the rate of increase of
PSA is not a more-speciﬁc marker for prostate cancer [53] and is
not a good biomarker for distinguishing BPH from prostate cancer.
Hence, a new diagnostic marker to replace or complement PSA needs
to be identiﬁed. Pin1 expression is associated with clinicopathologic
features of different types of tumors [17,54,55], and these results indi-
cate that Pin1 may have a role in tumor development and metastasis.
2065K.-H. Lee et al. / Biochimica et Biophysica Acta 1843 (2014) 2055–2066Ayala et al. [14] reported that patients with high Pin1 expression had
worse survival than thosewithout Pin1 expression, and they concluded
that Pin1 is an excellent prognosticmarker for prostate cancer. Our clin-
ical studies indicated that there was an inverse correlation between the
expressions of miR-296-5p and Pin1 in prostate cancer clinical speci-
mens. MiR-296-5p was lower in resected tissues of prostate cancer pa-
tients and is a negative regulator of Pin1. Thus, a combination of the
expression levels ofmiR-296-5p and Pin1may provide potential clinical
applications in the diagnosis and prognosis of prostate cancer.
In conclusion, we demonstrated that the loss of miR-296-5p and
concomitant elevation of Pin1 are most pronounced in prostate cancer.
We also demonstrated that Pin1 is negatively regulated by miR-296-5p
at the post-transcriptional level through a speciﬁc target site within the
3′-UTR. Thus, we postulated that the loss of miR-296-5p may represent
a progressive molecular lesion in the development of more-aggressive
disease. This study suggests that targeting themiR-296-5p/Pin1 interac-
tion or perturbing miR-296-5p expression may open a new therapeutic
avenue for the development of anticancer therapies for prostate cancer
patients.
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